Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy ; volume:13 ; number:1 ; day:7 ; month:12 ; year:2020 ; pages:1-22 ; date:12.2020
Journal of hematology & oncology ; 13, Heft 1 (7.12.2020), 1-22, 12.2020
- Urheber
-
Yilmaz, Ahmet
Cui, Hanwei
Caligiuri, Michael A.
Yu, Jianhua
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-020-00998-9
- URN
-
urn:nbn:de:101:1-2021011518085418608437
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yilmaz, Ahmet
- Cui, Hanwei
- Caligiuri, Michael A.
- Yu, Jianhua
- SpringerLink (Online service)
Ähnliche Objekte (12)
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
Developing new chimeric antigen receptor (CAR)-engineered natural killer cells targeting ovarian cancer stem cells
Cancer-testis antigen specific chimeric antigen receptor T cells for cancer immunotherapy
CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia
Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV
Cellular Immunotherapy for Hematological Disorders : From Allogeneic Stem Cell Transplantation to Chimeric Antigen Receptor-engineered T-cell Application
High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
Developing new chimeric antigen receptor (CAR)-engineered natural killer cells targeting ovarian cancer stem cells
Cancer-testis antigen specific chimeric antigen receptor T cells for cancer immunotherapy
CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia
Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV
Cellular Immunotherapy for Hematological Disorders : From Allogeneic Stem Cell Transplantation to Chimeric Antigen Receptor-engineered T-cell Application
High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
Developing new chimeric antigen receptor (CAR)-engineered natural killer cells targeting ovarian cancer stem cells
Cancer-testis antigen specific chimeric antigen receptor T cells for cancer immunotherapy
CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia
Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV
Cellular Immunotherapy for Hematological Disorders : From Allogeneic Stem Cell Transplantation to Chimeric Antigen Receptor-engineered T-cell Application